JW Pharmaceutical Corporation reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 291.32 million compared to KRW 1,763.71 million a year ago. Net income was KRW 5,090.47 million compared to KRW 2,951.41 million a year ago. Basic earnings per share from continuing operations was KRW 218.4466 compared to KRW 126.2136 a year ago. Basic earnings per share was KRW 218.4466 compared to KRW 126.2136 a year ago. For the nine months, sales was KRW 3,847.1 million compared to KRW 3,565.65 million a year ago. Net income was KRW 5,758.9 million compared to net loss of KRW 8,292.16 million a year ago. Basic earnings per share from continuing operations was KRW 247.5728 compared to basic loss per share from continuing operations of KRW 355.3398 a year ago. Basic earnings per share was KRW 247.5728 compared to basic loss per share of KRW 355.3398 a year ago.